Korean Circ J.  2016 May;46(3):307-308. 10.4070/kcj.2016.46.3.307.

Angiotensin Receptor Blocker for Stroke Prevention in Atrial Fibrillation: beyond Blood Pressure Lowering?

• Choi EK

• KMID: 2344442
• DOI: http://doi.org/10.4070/kcj.2016.46.3.307

Abstract

No abstract available.

MeSH Terms

Angiotensins*
Atrial Fibrillation*
Blood Pressure*
Stroke*
Angiotensins

Reference

1. European Heart Rhythm Association. European Association for Cardio-Thoracic Surgery. Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31:2369–2429.

2. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010; 55:2299–2307.

3. Touyz RM, Schiffrin EL. Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension. Hypertension. 1993; 22:853–862.

4. Remková A, Remko M. The role of renin-angiotensin system in prothrombotic state in essential hypertension. Physiol Res. 2010; 59:13–23.

5. Murad JP, Espinosa EV, Ting HJ, Khasawneh FT. Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Ther. 2012; 17:308–314.

6. Sakamoto T, Kudoh T, Sakamoto K, Matsui K, Ogawa H. Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study. Hypertens Res. 2014; 37:513–518.

7. Choi JI, Jung JS, Kim MK, et al. Effects of angiotensin-II receptor blocker on inhibition of thrombogenicity in a canine atrial fibrillation model. Korean Circ J. 2016; 46:335–342.